<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262492</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01415-52</org_study_id>
    <nct_id>NCT04262492</nct_id>
  </id_info>
  <brief_title>International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants</brief_title>
  <acronym>OBSTINATE</acronym>
  <official_title>OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stéphane Zuily</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Society on Thrombosis and Haemostasis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry, currently being established will ensure consistency of data collection and
      provide safety information in non high-risk APS patients currently on DOACs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">April 2028</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Rate of Recurrent Thrombosis</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of Recurrent Thrombosis either arterial, venous or microvascular confirmed by a relevant exam</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of Bleeding either severe or major or clinically relevant non-major bleeding according to ISTH classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Non-Criteria Manifestations</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of Non-Criteria Manifestations according to Sydney criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of patients who have a good adherence to oral anticoagulants assessed by the Girerd questionnaire</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <condition>Thrombosis</condition>
  <condition>Anticoagulants Causing Adverse Effects in Therapeutic Use</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID</description>
    <other_name>Dabigatran</other_name>
    <other_name>Apixaban</other_name>
    <other_name>Edoxaban</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Thrombotic APS patients according to revised Sapporo-Sydney criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient receiving a comprehensive information about the study, and not opposed to
             participate

          -  Age ≥ 18 yo

          -  Classification of definite APS according to revised Sapporo-Sydney criteria

          -  Direct oral anticoagulant treatment prescribed during at least 6 months or with the
             possibility of follow-up of at least 6 months

        Exclusion Criteria:

          -  Incomplete revised Sapporo-Sydney criteria

          -  No data regarding the recurrent thrombosis

          -  Pregnant woman

          -  Age &lt; 18 yo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Virginie Dufrost, MD, MSc</last_name>
    <phone>+33383157828</phone>
    <email>v.dufrost@chru-nancy.Fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stéphane Zuily</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphane Zuily, MD, PhD</last_name>
      <phone>+33383157354</phone>
      <email>s.zuily@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Virginie Dufrost, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Wahl, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Zuily, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://cdn.ymaws.com/www.isth.org/resource/resmgr/subcommittees/registry_on_doacs_in_aps_pro.pdf</url>
    <description>ISTH SSC LA/aPL project</description>
  </link>
  <link>
    <url>https://apsnancy.com/Research-Projects.php</url>
    <description>OBSTINATE webpage</description>
  </link>
  <reference>
    <citation>Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, Wahl D, Zuily S. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018 Oct;17(10):1011-1021. doi: 10.1016/j.autrev.2018.04.009. Epub 2018 Aug 11. Review.</citation>
    <PMID>30103045</PMID>
  </reference>
  <reference>
    <citation>Dufrost V, Risse J, Wahl D, Zuily S. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Response to Comment. Curr Rheumatol Rep. 2017 Aug;19(8):52. doi: 10.1007/s11926-017-0676-2.</citation>
    <PMID>28741234</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Stéphane Zuily</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>antiphospholipid syndrome</keyword>
  <keyword>direct oral anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

